OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologicsBusiness Overview: OSSPL is a subsidiary of Strides Pharma Ltd. The...
OneSource Specialty Pharma's FY26 BRSR shows improved environmental performance with major NOx/SOx emission cuts and enhanced energy/water efficiency from new systems. Accounts payable days doubled to 163.75, while related party sales share dropped to 29.12%. CSR spend reached ₹2.15 Cr.
OneSource Specialty Pharma allotted 2,900 equity shares to employees under its ESOP 2021 scheme. This increases the company's paid-up share capital by INR 2,900, reflecting employee share ownership.
OneSource Pharma announced a strategic manufacturing partnership with Formycon AG for biosimilars. OneSource will provide integrated Drug Substance & Product manufacturing from its Bangalore facility, leveraging its expertise to boost global access to affordable, high-quality biologics.
OneSource clarifies DRL's supply delay will have no material financial impact. The company has ample demand from other customers, including for Canada, and is significantly expanding capacities, reinforcing its growth plans.
OneSource Pharma's Bengaluru sterile product facility inspection concluded with one observation. The company will provide a comprehensive response. This operational update is key for compliance.
